Pharmaceutical giant Pfizer pursued a staggering $105 million Medicaid reimbursement lawsuit against the Trump administration while seeking regulatory approval for its COVID-19 vaccine, reveals explosive court documents.
Exclusive investigation reveals how drug companies are profiting from body shame through Ozempic and Wegovy injections, while eating disorder experts warn of potentially devastating health consequences.
Five years into her tenure, CEO Emma Walmsley has stabilised GSK's ship, but looming patent cliffs and vaccine market pressures cast shadows over ambitious growth targets.
A groundbreaking HIV prevention injection offering six months of protection with lenacapavir will be available in 120 lower-income countries by 2027 through a landmark access agreement.
Eli Lilly accuses the UK of having Europe's most challenging drug pricing system, threatening patient access to new medicines like Mounjaro amid ongoing NHS negotiations.
Financial markets experienced significant volatility as gold hit record highs while pharmaceutical giant Eli Lilly faced pressure over drug pricing concerns. Get the latest analysis on today's market movements.
B&Q owner Kingfisher hit by market turmoil following OECD's downgraded UK growth forecast, as Chancellor Rachel Reeves faces immediate economic pressure.
Shares in Donald Trump's Truth Social parent company surged by as much as 59% in their first day of trading, creating a massive paper fortune for the former president despite the platform's modest revenue.
Former President Donald Trump's confusion between Tylenol and hydroxychloroquine during the presidential debate triggers a sharp sell-off in pharmaceutical stocks, with Kenvue shares taking a significant hit.
Pharmaceutical giant Kenvue has issued a stern rebuke to Donald Trump after he suggested the COVID-19 vaccine was comparable to the Tylenol murders, calling the analogy 'irresponsible'.
A senior Chinese pharmaceutical executive has been sentenced to 15 years in a US prison for conspiring to manufacture and distribute fentanyl, marking a significant victory in the transatlantic fight against the opioid crisis.
Exclusive insight into how NHS England's shrewd negotiation tactics secure massive discounts on vital medicines, from cancer treatments to rare disease drugs, ensuring sustainable healthcare funding.
In a sudden move, Pets at Home CEO Lyssa McGowan steps down after a challenging two-year tenure. The surprise leadership shake-up triggers a sharp drop in the company's share price and raises questions about the pet retail giant's future strategy.
Breakthrough obesity drug Orforglipron shows unprecedented results in clinical trials, reducing body weight by a fifth and offering new hope for millions struggling with weight management in the UK.
Former chief scientific adviser Sir Patrick Vallance warns that dwindling investment in medical research and innovation threatens the future of the NHS and patient care. Discover the urgent call for action.
Pharmaceutical giant Merck to manufacture flagship cancer drug Lynparza at new €1 billion Irish facility, dealing significant blow to UK's life sciences sector and raising fresh post-Brexit trade concerns.
Exclusive analysis reveals how a potential Trump presidency could jeopardise Britain's NHS medicine pricing, forcing UK patients to pay US-style pharmaceutical costs.
Major pharmaceutical giants AstraZeneca, MSD (Merck), and Eli Lilly announce massive new investments in UK research and manufacturing, signalling a major vote of confidence in the British life sciences sector following the US election result.
Tesla faces a staggering $50bn market valuation loss as shareholders reject Elon Musk's colossal $56bn pay package, triggering a dramatic share price collapse and raising serious corporate governance concerns.
Tesla shares plummet as Elon Musk's aggressive pivot to AI and robotics sparks a massive investor sell-off, wiping billions from the company's valuation and raising serious questions about its future direction.
Shares in Donald Trump's Truth Social parent company, DJT, have nosedived, erasing billions from its market value and raising serious questions about its long-term viability.
Pharmaceutical giant AstraZeneca has paused plans for its new £500 million global headquarters in Cambridge, citing an 'unfavourable' UK economic climate and sending shockwaves through the business community.
Groundbreaking research uncovers a disturbing correlation between widely prescribed drugs, including beta-blockers and anti-anxiety medications, and a sharp increase in suicide risks and depression in children and young adults. Experts are calling for urg
Pharmaceutical giant AstraZeneca pauses its major £200m Cambridge research centre expansion, citing global strategic review and UK economic uncertainty in post-Brexit landscape.
Sanofi executive warns of UK's worsening medicines access crisis, citing post-Brexit regulations, NICE hurdles, and a pricing system that deters investment and innovation.
Pharmaceutical giant MSD, known as Merck in the US, is significantly expanding its UK presence with a new state-of-the-art research hub in London, generating over 125 new high-skilled jobs and reinforcing the city's status as a global life sciences leader
THG faces a severe stock market crash after reporting disappointing Q3 revenue, with its key MyProtein brand struggling in European markets. The company slashes its full-year profit forecast, sparking investor panic.
Trainline's stock value nosedived after the Labour Party's election victory, with plans to create a new state-owned ticketing operator sending shockwaves through the transport sector.
Elon Musk's fortune has dramatically declined by over $13 billion in a single day as Tesla shares plummet, dethroning him from his position as the world's wealthiest person amidst a challenging market period for his companies.
Exclusive report reveals Donald Trump pressured US health officials to accelerate vaccine approval for political gain ahead of the 2020 election, according to congressional investigation.